OpenAlex | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Work

Year: 2012

Type: article

Source: The Lancet Oncology

Authors Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí +52 more

Institutions USP Institut Universitari Dexeus, Institut Català d'Ornitologia, Institut Català d'Oncologia, Centre François Baclesse, Hôpital Dupuytren +44 more

Cites: 23

Cited by: 5,234

Related to: 10

FWCI: 383.2

Citation percentile (by year/subfield): 100

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

Sustainable Development Goal Good health and well-being

Open Access status: closed